| Primary |
| Ovarian Cancer |
18.7% |
| Neoplasm |
9.4% |
| Hypertension |
9.0% |
| Neuroblastoma |
7.4% |
| Ovarian Cancer Recurrent |
7.4% |
| Pain |
7.3% |
| Prophylaxis |
4.9% |
| Small Cell Lung Cancer Stage Unspecified |
4.8% |
| Vestibular Neuronitis |
4.7% |
| Nausea |
4.5% |
| Cervix Carcinoma |
4.0% |
| Neoplasm Malignant |
2.9% |
| Drug Use For Unknown Indication |
2.6% |
| Constipation |
2.5% |
| Glioblastoma |
2.0% |
| Vomiting |
1.9% |
| Non-small Cell Lung Cancer |
1.7% |
| Urinary Tract Infection |
1.6% |
| Anxiety |
1.5% |
| Atrial Fibrillation |
1.4% |
|
| Vomiting |
18.5% |
| Thrombocytopenia |
17.6% |
| Pyrexia |
9.6% |
| Febrile Bone Marrow Aplasia |
7.5% |
| White Blood Cell Count Decreased |
5.4% |
| Respiratory Failure |
3.9% |
| Dehydration |
3.6% |
| Dyspnoea |
3.3% |
| Ileus |
3.3% |
| Urinary Tract Infection |
3.0% |
| Nausea |
2.7% |
| Pain |
2.7% |
| Pneumonia |
2.7% |
| Weight Decreased |
2.7% |
| Dizziness |
2.4% |
| Lethargy |
2.4% |
| Muscular Weakness |
2.4% |
| Rash |
2.4% |
| General Physical Health Deterioration |
2.1% |
| Neutropenia |
2.1% |
|
| Secondary |
| Ovarian Cancer |
17.0% |
| Colorectal Cancer |
15.8% |
| Neuroblastoma |
11.5% |
| Drug Use For Unknown Indication |
8.1% |
| Prophylaxis |
7.0% |
| Acute Myeloid Leukaemia |
5.7% |
| Glioblastoma |
4.6% |
| Squamous Cell Carcinoma Of The Cervix |
4.2% |
| Acute Lymphocytic Leukaemia |
3.4% |
| Ewing's Sarcoma |
3.4% |
| Product Used For Unknown Indication |
3.1% |
| Premedication |
2.1% |
| Alveolar Rhabdomyosarcoma |
2.0% |
| Hypertension |
2.0% |
| Vomiting |
1.9% |
| Chemotherapy |
1.8% |
| Colon Cancer Metastatic |
1.8% |
| Colon Cancer |
1.5% |
| Neoplasm |
1.5% |
| Ovarian Cancer Recurrent |
1.5% |
|
| Thrombocytopenia |
14.0% |
| Pulmonary Alveolar Haemorrhage |
11.6% |
| Vomiting |
11.6% |
| White Blood Cell Count Decreased |
7.4% |
| Infection |
6.2% |
| Sepsis |
5.8% |
| Colorectal Cancer |
5.0% |
| Neutropenia |
4.1% |
| Anaemia |
3.7% |
| Diarrhoea |
3.7% |
| Multiple Myeloma |
3.3% |
| Staphylococcal Infection |
3.3% |
| Interstitial Lung Disease |
2.9% |
| Death |
2.5% |
| Febrile Neutropenia |
2.5% |
| Neutrophil Count Decreased |
2.5% |
| Pain |
2.5% |
| Pancreatitis Acute |
2.5% |
| Renal Failure Chronic |
2.5% |
| Respiratory Failure |
2.5% |
|
| Concomitant |
| Drug Use For Unknown Indication |
18.8% |
| Ovarian Cancer |
12.3% |
| Product Used For Unknown Indication |
9.3% |
| Ovarian Cancer Recurrent |
6.3% |
| Colorectal Cancer |
6.1% |
| Breast Cancer |
4.4% |
| Prophylaxis |
4.3% |
| Pain |
4.1% |
| Rectal Cancer Metastatic |
4.1% |
| Pancreatic Neuroendocrine Tumour |
3.8% |
| Colon Cancer Metastatic |
3.7% |
| Colon Cancer Recurrent |
3.4% |
| Acute Lymphocytic Leukaemia |
3.1% |
| Hypertension |
3.1% |
| Prophylaxis Of Nausea And Vomiting |
3.0% |
| Rectal Cancer Recurrent |
2.8% |
| Nausea |
1.9% |
| Burkitt's Lymphoma |
1.8% |
| Chemotherapy |
1.8% |
| Multiple Myeloma |
1.8% |
|
| Renal Failure Chronic |
11.1% |
| Interstitial Lung Disease |
7.1% |
| Thrombocytopenia |
7.1% |
| Urge Incontinence |
7.1% |
| White Blood Cell Count Abnormal |
7.1% |
| Vomiting |
6.1% |
| Disease Progression |
5.1% |
| Pyrexia |
5.1% |
| Thrombosis |
5.1% |
| Congestive Cardiomyopathy |
4.0% |
| Pain |
4.0% |
| Pneumonia |
4.0% |
| Sepsis |
4.0% |
| Septic Shock |
4.0% |
| White Blood Cell Count Decreased |
4.0% |
| Acute Graft Versus Host Disease |
3.0% |
| Bone Marrow Failure |
3.0% |
| Death |
3.0% |
| Haemoglobin Abnormal |
3.0% |
| Melaena |
3.0% |
|
